Here is a new MSS-CRC immunotherapy trial opening up at Johns Hopkins:
"Phase 2 Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer"
It uses a very cool genetically modified listeria technology as therapeutic vaccine + a PD1 inhibitor.
Like all therapeutic vaccines, this technology has shown limited clinical efficacy in the past but many scientists believe that by now adding a PD1 inhibitor, there is a reasonable chance that clinical efficacy may happen.
Time & clinical trial testing will tell but I think there is a chance that a number of previously disappointing technologies (vaccination, oncolytic viruses etc) may be reinvigorated via PD1 inhibitor combo trials.